These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9559790)

  • 21. Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines.
    Piscitelli SC; Amatea MA; Vogel S; Bechtel C; Metcalf JA; Kovacs JA
    Antimicrob Agents Chemother; 1996 Jan; 40(1):161-5. PubMed ID: 8787899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children.
    Abreu T; Plaisance K; Rexroad V; Nogueira S; Oliveira RH; Evangelista LA; Rangel R; Silva IS; Knupp C; Lambert JS
    Antimicrob Agents Chemother; 2000 May; 44(5):1375-6. PubMed ID: 10770783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial.
    Drusano GL; Yuen GJ; Lambert JS; Seidlin M; Dolin R; Valentine FT
    Ann Intern Med; 1992 Apr; 116(7):562-6. PubMed ID: 1347442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.
    Rongkavilit C; Thaithumyanon P; Chuenyam T; Damle BD; Limpongsanurak S; Boonrod C; Srigritsanapol A; Hassink EA; Hoetelmans RM; Cooper DA; Lange JM; Ruxrungtham K; Phanuphak P
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3585-90. PubMed ID: 11709344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.
    Kline MW; Fletcher CV; Harris AT; Evans KD; Brundage RC; Remmel RP; Calles NR; Kirkpatrick SB; Simon C
    J Pediatr; 1998 Mar; 132(3 Pt 1):543-6. PubMed ID: 9544920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine.
    Shelton MJ; Adams JM; Hewitt RG; Steinwandel C; DeRemer M; Cousins S; Morse GD
    Pharmacotherapy; 1997; 17(3):438-44. PubMed ID: 9165548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
    Shelton MJ; Mei H; Hewitt RG; Defrancesco R
    Antimicrob Agents Chemother; 2001 Jan; 45(1):298-300. PubMed ID: 11120981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Didanosine measurement by radioimmunoassay.
    DeRemer M; D'Ambrosio R; Morse GD
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1331-4. PubMed ID: 8725995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus.
    Zhou XJ; Squires K; Pan-Zhou XR; Bernhard S; Agrofoglio L; Kirk M; Duchin KL; Sommadossi JP
    J Clin Pharmacol; 1997 Mar; 37(3):201-13. PubMed ID: 9089422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients.
    Becher F; Landman R; Mboup S; Kane CN; Canestri A; Liegeois F; Vray M; Prevot MH; Leleu G; Benech H
    AIDS; 2004 Jan; 18(2):181-7. PubMed ID: 15075534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.
    Montaner JS; Zala C; Conway B; Raboud J; Patenaude P; Rae S; O'Shaughnessy MV; Schechter MT
    J Infect Dis; 1997 Apr; 175(4):801-6. PubMed ID: 9086133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zalcitabine population pharmacokinetics: application of radioimmunoassay.
    Adams JM; Shelton MJ; Hewitt RG; DeRemer M; DiFrancesco R; Grasela TH; Morse GD
    Antimicrob Agents Chemother; 1998 Feb; 42(2):409-13. PubMed ID: 9527795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.
    Csajka C; Marzolini C; Fattinger K; Décosterd LA; Telenti A; Biollaz J; Buclin T
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3226-32. PubMed ID: 15328077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects.
    Damle BD; Kaul S; Behr D; Knupp C
    J Clin Pharmacol; 2002 Jul; 42(7):791-7. PubMed ID: 12092746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922.
    Pavia-Ruz N; Rossouw M; Sáez-Llorens X; Bunupuradah T; Taylor M; Yang R; Sevinsky H; Krystal M; Lataillade M; Seekins D; Biguenet S
    Pediatr Infect Dis J; 2015 Dec; 34(12):1355-60. PubMed ID: 26379163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G
    Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Didanosine, a new antiretroviral drug. A review.
    Franssen RM; Meenhorst PL; Koks CH; Beijnen JH
    Pharm Weekbl Sci; 1992 Oct; 14(5):297-304. PubMed ID: 1437513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD4+ cell count decline despite HIV suppression: a probable didanosine-valganciclovir interaction.
    Tseng AL; Salit IE
    Ann Pharmacother; 2007 Mar; 41(3):512-7. PubMed ID: 17341536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new model for the population pharmacokinetics of didanosine in healthy subjects.
    Velasque LS; Estrela RC; Suarez-Kurtz G; Struchiner CJ
    Braz J Med Biol Res; 2007 Jan; 40(1):97-104. PubMed ID: 17225002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.